Executives On The Move: Precision Biosciences, Revolution Medicines and More
Recent executive changes in the industry include C-suite changes at Precision Biosciences and Revolution Medicines. Meanwhile, new directors were appointed at Sanofi and Arcutis Biotherapeutics.
You may also be interested in...
The US firm’s oral plasma kallikrein inhibitor was associated with liver elevations in a number of Phase II patients, prompting a trial termination and shift in focus to an on-demand program.
The US firm’s nanoparticle candidate has disappointed in a late-stage ALS trial but experts say secondary survival data could prove a silver lining given an increasingly flexible US regulatory environment.
After highlighting oncology drugs pegged to make a splash next year with the help of Biomedtracker, Scrip takes a look at seven potential blockbusters across a range of therapeutic areas including neurology, dermatology and blood disorders slated for approval next year.